,

Rheumatic Immune-Related Adverse Events, An Issue of Rheumatic Disease Clinics of North America

Specificaties
Gebonden, blz. | Engels
Elsevier Health Sciences | e druk, 2025
ISBN13: 9780443294006
Rubricering
Elsevier Health Sciences e druk, 2025 9780443294006
Onderdeel van serie The Clinics: Internal Medicine
€ 142,24
Levertijd ongeveer 8 werkdagen

Samenvatting

In this issue of Rheumatic Disease Clinics, guest editors Drs. Alexa Simon Meara and David Liew bring their considerable expertise to the topic of Rheumatic Immune-Related Adverse Events. Immune checkpoint inhibitors sometimes cause rheumatic-disease-like symptoms, or rheumatic immune-related adverse events (irAEs). In this issue, top experts discuss the utility of laboratory investigations for rheumatic irAEs; the future of biomarkers in rheumatic irAEs; integrating rheumatic irAE research and care into an oncological milieu; patient voices in rheumatic irAE care and research; polymyalgia rheumatica irAEs; inflammatory arthritis irAEs: current approaches to management; and more.Contains 15 relevant, practice-oriented topics including myositis irAEs; sicca symptom irAEs; de novo connective tissue disorders as irAEs; imaging in rheumatic irAEs; combining biologic DMARDs with immune checkpoint inhibitors; the impact of DMARDs and glucocorticoids on cancer response to immune checkpoint inhibitors; and moreProvides in-depth clinical reviews on rheumatic immune-related adverse events, offering actionable insights for clinical practicePresents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews

Specificaties

ISBN13:9780443294006
Taal:Engels
Bindwijze:Gebonden

Inhoudsopgave

Pre-existing Autoimmune Diseases and Immune Checkpoint Inhibitors for Cancer Treatment: Considerations About Initiation, Flares, Immune-Related Adverse Events, and Cancer Progression<br>Mimickers of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis<br>The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events<br>The Current and Future of Biomarkers of Immune Related Adverse Events<br>Immunotherapy Toxicity Management in Clinical Practice: Building the Clinical Infrastructure for Immune-related Adverse Event Evaluation and Care<br>Patient Voices in Rheumatic Immune-related Adverse Events<br>Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica<br>Immune Checkpoint Inhibitor-induced Inflammatory Arthritis: Current Approaches to Management<br>Immune Checkpoint Inhibitor-induced Myositis<br>Immune Checkpoint Inhibitor-induced Sicca Syndrome<br>De novo Connective Tissue Disorders as Immune-related Adverse Events<br>Imaging in Rheumatic Immune-related Adverse Events<br>The Need for Classification Criteria of Immune Checkpoint Inhibitor-induced inflammatory Arthritis: A Scoping Review<br>Impact of Non-steroidal Anti-inflammatory Drugs, Glucocorticoids, and Disease[1]Modifying Anti-Rheumatic Drugs on Cancer Response to Immune Checkpoint Inhibitor Therapy
€ 142,24
Levertijd ongeveer 8 werkdagen

Rubrieken

    Personen

      Trefwoorden

        Rheumatic Immune-Related Adverse Events, An Issue of Rheumatic Disease Clinics of North America